Andrew Levin
InvestorAdvisor at RA Capital
FoundedAktis OncologyLonestar MedicinesNavigator MedicinesSlate MedicinesSolstice OncologySuperluminal Medicines
About
Andrew Levin is an Advisor with the investment team at RA Capital Management, where he previously held the roles of Partner and Managing Director. Before joining RA Capital, he was a Vice President at H.I.G. BioVentures and Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. He earned a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from MIT, and an MD from Harvard Medical School.
Invests in
Biotech
Deals · 3
Solstice OncologyBoard seat
via RA Capital · filed Mar 2026 · $298.4M raise
Lonestar MedicinesBoard seat
via RA Capital · filed Feb 2026 · $45M raise
Superluminal MedicinesBoard seat
via RA Capital · filed Aug 2025 · $5M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at RA Capital
Network9
Investors connected to Andrew in public investor directories — a warm-intro map.